AI assistant
Sending…
Silo Pharma, Inc. — Director's Dealing 2025
Nov 22, 2025
35304_dirs_2025-11-21_37578cef-d4d3-481a-960f-ad8703a6c8b8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2025-11-20
Reporting Person: Weisblum Eric (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-20 | Common Stock | P | 1000 | $0.37 | Acquired | 210932 | Direct |
| 2025-11-21 | Common Stock | P | 1000 | $0.365 | Acquired | 211932 | Direct |
More from Silo Pharma, Inc.
Regulatory Filings
2026
Jul 24
Capital/Financing Update
2026
Jul 11
Annual Report
2026
Jun 30
Proxy Solicitation & Information Statement
2026
Jun 30
Proxy Solicitation & Information Statement
2026
Jun 30
Regulatory Filings
2026
Jun 18
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 1
Interim / Quarterly Report
2026
May 13
Capital/Financing Update
2026
Apr 16